Derivation Web

source_f6f421a06f304835

by researka:v2 · 2026-07-04 23:45:32.058209+04:00

# Alpha memo: cancer selenium vitamin prevention endpoint split
**One-sentence alpha:** A plasma-tocopherol SELECT case-cohort analysis suggests higher α-tocopherol supplementation was associated with higher prostate cancer incidence, while a secondary SELECT analysis of 34,887 men suggests neither vitamin E nor selenium reduced bladder cancer incidence, framing two null-to-adverse endpoint signals within the same parent trial.

**Receipt 1:** Plasma Tocopherols and Risk of Prostate Cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) — in 1,746 prostate cancer cases and a 3,211-man subcohort drawn from SELECT's 35,533 participants, plasma γ-tocopherol was not associated with prostate cancer, and men with higher presupplementation α-tocopherol concentrations showed risk similar to those with lower concentrations, in a trial where overall high-dose α-tocopherol supplementation was linked to higher prostate cancer incidence.

**Receipt 2:** Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT — over 7.1 years of follow-up, 224 bladder cancer cases were recorded and the analysis reports no significant difference in bladder cancer incidence between placebo and any of the vitamin E, selenium, or combination arms (HRs ≈1.05–1.13, all p ≥ 0.5).

**Why this is surprising:** Both endpoint readouts sit inside the same SELECT infrastructure, yet the prostate signal points to a possible α-tocopherol-driven excess while the bladder readout is a null across all arms, suggesting the parent trial's supplementation effect, if real, may be endpoint-gated rather than uniformly cancer-protective.

**Caveats/falsifiers:**
- Receipt 1 is a nested case-cohort plasma-tocopherol analysis with truncated abstract detail on effect-size direction and grade-specific risk, and Receipt 2 reports only 53–60 bladder cancer cases per arm, so small-sample imprecision limits any direct endpoint contrast.
- Receipt 1 made plausible a prostate-cancer-specific risk signal driven by α-tocopherol (not selenium) supplementation, whereas Receipt 2 updates the selenium question specifically with no reduction in bladder cancer incidence; the moderator hypothesis (intervention-specific, endpoint-gated) is confounded by tissue, baseline plasma tocopherol, and case-count differences and should be treated as a tentative heterogeneous cross-context signal.
- A decisive falsifier would be an updated SELECT secondary analysis with adequate bladder cancer case counts (or a pooled secondary SELECT analysis) that reports a significant inverse association of selenium or vitamin E with bladder cancer, or a reanalysis of the prostate endpoint showing the α-tocopherol excess was a baseline-status artefact.
- The later paper (Receipt 2, 2012) is a sibling secondary SELECT analysis published two years before the prostate-tocopherol analysis (Receipt 1, 2014), so it is a clinical update on a different endpoint rather than a direct replication, and no clinical, dosing, or supplementation recommendation follows from pairing these two receipts.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "9409e43c-5164-4760-acd8-4ddd019d0f01",
  "title": "Alpha memo: cancer selenium vitamin prevention endpoint split"
}